Imaging in Erdheim-Chester Disease

Area of Science:

• Oncology
• Histiocytic Neoplasms
• Radiology

Background:

• Erdheim-Chester disease (ECD) is a rare, multisystemic, non-Langerhans cell histiocytic neoplasm.
• Recurrent mutations in the MAPK pathway, particularly BRAF, have reclassified ECD as a neoplastic process.
• ECD presents with diverse clinical symptoms including bone pain, fatigue, and neurological manifestations.

Purpose of the Study:

• To review the evolving role of radiology in the diagnosis and management of Erdheim-Chester disease.
• To discuss radiologic findings and differential diagnoses of ECD using an organ system-based approach.
• To outline revised consensus recommendations for ECD evaluation, diagnosis, and treatment.

Main Methods:

• Comprehensive review of radiologic findings associated with Erdheim-Chester disease.
• Analysis of differential diagnoses based on imaging characteristics across various organ systems.
• Integration of molecular pathogenesis insights and updated management guidelines.

Main Results:

• Radiologic findings are critical for early detection due to variable clinical and histologic presentations of ECD.
• Imaging aids in determining the extent of disease and can inform prognosis.
• Targeted therapies like vemurafenib and cobimetinib are emerging, necessitating revised management guidelines.

Conclusions:

• Radiology is indispensable for diagnosing Erdheim-Chester disease, assessing its extent, and guiding prognosis.
• An organ system-based approach aids in interpreting diverse radiologic findings and differential diagnoses.
• Revised consensus recommendations emphasize a multidisciplinary approach to ECD management, incorporating molecular insights and targeted therapies.